RA-led $35M round clears path for Cerebral’s epilepsy Phase II

Cerebral is looking to take its epilepsy drug delivery system into an international trial after proof-of-concept data for CT-010 enabled the company to raise a tranched $35 million series B led by new investor RA Capital Management.

The system delivers a continuous dose intracerebroventricularly of valproic acid -- a standard epilepsy therapy given orally as a pill. The drug-device combination comprises a pump inserted into the abdomen, which connects to a catheter that extends up into the scalp and delivers a reformulation of valproic acid...